Drug Search Results
More Filters [+]

Artesunate

Alternative Names: artesunate
Latest Update: 2024-08-15
Latest Update Note: Clinical Trial Update

Product Description

Artesunate injection is used to treat severe malaria. This medicine is also used together with other medicines (eg, 8-aminoquinoline medicine) to treat severe malaria caused by Plasmodium ovale or Plasmodium vivax. (Sourced from: https://www.mayoclinic.org/drugs-supplements/artesunate-intravenous-route/side-effects/drg-20489625?p=1)

Mechanisms of Action: NOTCH Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Belgium | Brazil | China | Colombia | Croatia | Czech | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Indonesia | Ireland | Italy | Latvia | Lithuania | Malaysia | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Slovakia | Slovenia | South Africa | Sweden | Thailand | Ukraine | United Kingdom | United States | Vietnam

Approved Indications: Malaria | Malaria, Vivax

Known Adverse Events: Malaria | Hemoglobinuria

Company: Ministry of Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Artesunate

Countries in Clinic: Bangladesh, Burkina Faso, Cambodia, Canada, Congo, Gambia, Guinea, Kenya, Korea, Niger, Nigeria, Rwanda, South Africa, Tanzania, United States

Active Clinical Trial Count: 15

Highest Development Phases

Phase 3: COVID-19|Malaria, Falciparum

Phase 2: Carcinoma in Situ|Cervical Cancer|Friedreich Ataxia|Malaria|Papillomavirus Infections|Squamous Cell Carcinoma|Squamous Intraepithelial Lesions of the Cervix|Uterine Cancer|Uterine Cervical Dysplasia|Vulvar Cancer|Vulvar Diseases

Phase 1: Papilloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ART-AIN IIB-2

P2

Recruiting

Carcinoma in Situ|Squamous Cell Carcinoma|Squamous Intraepithelial Lesions of the Cervix|Papillomavirus Infections

2025-12-31

LCCC2236

P1

Recruiting

Cervical Cancer|Uterine Cancer|Uterine Cervical Dysplasia

2025-12-01

ART-CIN_IIB

P2

Recruiting

Uterine Cancer|Papillomavirus Infections|Uterine Cervical Dysplasia|Cervical Cancer

2025-07-31

anal HSIL HIV-

P2

Active, not recruiting

Carcinoma in Situ|Papillomavirus Infections|Squamous Intraepithelial Lesions of the Cervix|Squamous Cell Carcinoma

2024-12-28

Recent News Events